MedicalNewsToday weighs in on the Lucentis-Avastin debate: "Genentech (Hoffman - La Roche) manufactures two critically important pharmaceuticals, Lucentis and Avastin, which are both used for treatment of several common eye diseases - including age-related macular degeneration (AMD). Despite considerable clinical similarity, the price difference between these drugs is substantial, with Lucentis generally costing up to 100 times the equivalent treatment with Avastin. A National Institutes of Health (NIH) clinical trial titled, "Comparison of AMD Treatment Trials" (CATT), is currently under way to compare the safety and efficacy of the two drugs, and the results may have far-reaching economic implications for Genentech, patients, Medicare, and third party payors."
No comments:
Post a Comment